Avience Biomedicals SME IPO
Avience Biomedicals IPO — date, price band, GMP & allotment 2026
Avience Biomedicals IPO was open for subscription from 18 June 2026 to 22 June 2026. Incorporated in 2019, Avience Biomedicals Limited is a molecular diagnostics and biomedical products company focused on healthcare testing solutions. The company follows a business model centred on manufacturing and supplying diagnostic kits, reagents and laboratory products for healthcare institutions. Based in Noida, the company serves hospitals, diagnostic laboratories and healthcare providers across India
Stock price
Avience Biomedicals is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 17 September.
- Open 18 Jun 2026
- Close 22 Jun 2026
- Allotment 23 Jun 2026
- Refund/credit 24 Jun 2026
- Listing 25 Jun 2026
Issue summary
The terms of the offer, as filed.
| IPO Dates | 18 to 22 Jun, 2026 |
|---|---|
| Price Band | ₹196 – ₹208 |
| Face Value | ₹10 |
| Lot Size | 600 Shares |
| Issue Size | ₹30.24 Cr |
| Sale Type | Fresh capital only |
| Listing On | NSE SME |
| Registrar | Skyline Financial Services Private Limited |
| Min Investment | ₹ 2,49,600 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 600 shares at the ₹208 cut-off. The SME retail application is a fixed 2 lots; HNI starts at 3.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 2 | 1,200 | ₹2,49,600 |
| Retail (max) | 2 | 1,200 | ₹2,49,600 |
| HNI (min) | 3 | 1,800 | ₹3,74,400 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Operates in the fast-growing healthcare and molecular diagnostics sector.
- 02Focused product portfolio catering to hospitals and diagnostic laboratories.
- 03Rising demand for diagnostic testing supports long-term growth prospects.
- 04Experienced promoter group with healthcare industry exposure.
- 05Asset-backed manufacturing and distribution capabilities enhance scalability.
Risks · 5
- 01Business performance depends on regulatory approvals and healthcare compliance requirements.
- 02Intense competition from established diagnostic and biomedical companies may affect growth.
- 03Rapid technological changes could require continuous investment in product development.
- 04Dependence on healthcare spending and diagnostic testing demand may impact revenues.
- 05Relatively limited operating history compared to larger industry peers.
Three years of numbers
All figures in ₹ crore, as reported in the Avience Biomedicals offer document.
| Metric | 31 Jan 2026 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 66.07 | 56.52 | 34.65 |
| Total Income | 41.94 | 45.97 | 24.37 |
| Profit After Tax | 5.74 | 7.23 | 2.14 |
| EBITDA | 10.34 | 11.41 | 4.08 |
| NET Worth | 28.52 | 22.78 | 6.21 |
| Reserves and Surplus | 24.49 | 18.75 | 2.93 |
| Total Borrowing | 26.73 | 22.16 | 15.13 |
See how this IPO compares — view listing performance of all SME IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Avience Biomedicals RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Avience Biomedicals IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Post-Issue |
|---|---|
| EPS (₹) | ₹12.56 |
| P/E Ratio (x) | 16.56 |
| Market Cap at Offer Price (₹ Cr) | ₹95.06 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹208 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹30.24 Cr of the issue is earmarked to named objects.
About the company
The company is engaged in the manufacturing and distribution of molecular diagnostic kits, reagents and related healthcare products used by hospitals, laboratories and diagnostic centres. Its business model is based on developing and supplying testing solutions that support disease detection and clinical diagnostics. With increasing demand for advanced healthcare testing infrastructure, the company aims to expand its product portfolio and market reach across India.
Interested in this IPO? Check the live subscription status or browse all upcoming SME IPOs.
1800-12-04-636
The bankers & the filings
Who is running the book, and the documents this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Fintellectual Corporate Advisors Private Limited
1 issue handled1 of their issues has listed so far, and 1 opened above the issue price (average +4.2%). That is too small a sample to read as a hit rate.
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Avience Biomedicals?
The current Grey Market Premium is ₹145, or 69.7% over the issue price.
What is the Avience Biomedicals IPO price band?
₹196 to ₹208, on a face value of ₹10.
When is the allotment?
The basis of allotment is 23 June 2026, with listing on 25 June 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — Skyline Financial Services Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every SME and Mainboard issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
